flavone/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to a treatment regimen for cancer therapy, and, more particularly, to a treatment regimen for renal carcinoma. BACKGROUND OF THE INVENTION Attempts have been made recently to develop immunotherapies for the treatment of cancer based on stimulating

FIELD OF THE INVENTION The present invention relates to a treatment regimen for cancer therapy, and, more particularly, to a treatment regimen for renal carcinoma. BACKGROUND OF THE INVENTION Attempts have been made recently to develop immunotherapies for the treatment of cancer based on stimulating

FIELD OF THE INVENTION The present invention relates to a treatment regimen for cancers having cells which are susceptible to an interleukin-2 activated natural killer cell mediated anti-cancer effect, and, more particularly, to a treatment regimen for renal carcinoma. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I (as described

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to flavonoid derivatives and, more particularly, to a flavonoid derivative or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating cancer and

FIELD OF THE INVENTION The present invention relates generally to biology and medicine, and more particularly to compositions and methods for treating bladder and urinary tract cancers. BACKGROUND OF THE INVENTION New therapies and improved diagnoses of bladder cancer have significantly lowered the

FIELD OF INVENTION The present invention relates to an enantioselective synthesis of the (+)-trans enantiomer of pyrrolidines substituted with flavones, represented by the compounds of Formula 1 or salts thereof, which are inhibitors of cyclin dependant kinases and can be used for treatment of

FIELD OF THE INVENTION The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) (as described herein) or pharmaceutically acceptable salts, solvates, stereoisomers or diastereoisomers thereof for use in the treatment of

FIELD OF THE INVENTION The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) (as described herein) or pharmaceutically acceptable salts, solvates, stereoisomers or diastereoisomers thereof for use in the treatment of

TECHNICAL FIELD The present invention relates to a novel flavone derivative represented by the following formula (1): ##STR1## in which R.sub.1, R.sub.3 and R.sub.4 each independently represent hydrogen, halogen, hydroxy, alkyl, lower alkoxy, amino or nitro, R.sub.2 represents hydrogen, halogen,

BACKGROUND OF THE INVENTION The invention is generally related to the treatment of inflammatory conditions. More specifically, the invention is related to compositions containing inhibitors of mast cell activation and secretion such as a proteoglycan that are designed to be used as dietary

FIELD OF THE INVENTION The invention relates to a class of compounds which have a structure related to naturally and synthetically occurring flavanoids and to pharmaceutical uses of the compounds. TECHNICAL FIELD The development of multiple drug resistance represents an increasing problem in cancer

CROSS-REFERENCE TO RELATED APPLICATION This Application claims priority of Taiwan Patent Application No. 105117782, filed on Jun. 6, 2016, the entirety of which is incorporated by reference herein and made a part of this specification. BACKGROUND 1. Field of the Invention The present disclosure

FIELD OF THE INVENTION The present invention relates to novel dye-sulfenate compounds, and to phototherapeutic procedures using these compounds. BACKGROUND OF THE INVENTION The use of visible and near-infrared (NIR) light in clinical practice is growing rapidly. Compounds absorbing or emitting in